Delray Medical Center recently published a breakthrough study focusing on 5ALA (fluorescent guided surgery) for glioblastomas, with the team at the Mount Sinai Hospital. The clinical trial took place at Delray Medical Center, and led by Dr. Lloyd Zucker, Chief of Neurosurgery at Delray Medical Center. The study, taking place over a five-year period, is now published in the Journal of Neurosurgery, one of the largest peer reviewed neurosurgical journals in the world.
“I am honored to have participated in this incredible and innovative study with Mount Sinai. The medical community now has a better way to treat patients who have been diagnosed with glioblastoma brain tumors,” said Dr. Zucker. “Having Delray Medical Center be the site for published studies such as this one for fluorescent guided brain tumor surgery, shows how we are providing state of the art care right here in our community.”
Fluorescent guided surgery is used to give surgeons the ability to ‘see’ in a different wavelength of light that would otherwise be invisible to them. By combining this visual ability with the special dyes that glow in those wavelengths, surgeons can much more precisely target cancerous tumors and avoid injury to normal tissues.
